Company: ZURA
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0001104659-25-038042
Chunk: 39

Company: Zura Bio Ltd
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 39
---
 to May 2007 and Proctor and Gamble from November 1996 to October 1999, all of which were in a technical operations role. Dr. Whale holds a bachelor’s degree in Biochemistry and a master’s degree in Microbiology from the University of London, and a PhD in the purification and characterization of bacterial cell surface antigens from Robert Gordon University. 22

TABLE OF CONTENTS

EXECUTIVE COMPENSATION We have opted to comply with the executive compensation disclosure rules applicable to emerging growth companies and smaller reporting companies, as the Company qualifies as an “emerging growth company” under the Jumpstart Our Business Startups Act of 2012 and a “smaller reporting company” under the Exchange Act. The scaled down disclosure rules require compensation disclosure for our principal executive officer and our two most highly compensated executive officers other than the principal executive officer whose total compensation for 2024 exceeded $100,000 and who were serving as executive officers as of December 31, 2024, and up to two additional individuals who served as executive officers during the year ended December 31, 2024, but were not serving in such capacity as of December 31, 2024, if their total compensation is higher than any of the other named executive officers in the preceding group. We refer to these individuals as our “named executive officers.” For 2024, our named executive officers were: • Robert Lisicki, Chief Executive Officer and former President and Chief Operating Officer (1) ; • Someit Sidhu, former Chief Executive Officer (2) ; • Kim Davis, Chief Operating Officer, Chief Legal Officer and Corporate Secretary (3) ; and • Kiran Nistala, Chief Medical Officer and Head of Development. (1) Mr. Lisicki joined the Company as President and Chief Operating Officer, effective January 8, 2024. In connection with the Chief Executive Officer transition from Dr. Sidhu to Mr. Lisicki (the “CEO Transition”), Mr. Lisicki was promoted to the role of Chief Executive Officer and joined the Board as a non-independent director, effective as of April 8, 2024. (2) Dr. Sidhu transitioned from his role as Chief Executive Officer, effective April 8, 2024, and continues to serve on the Board as a non-independent director. (3) Ms. Davis was appointed Chief Operating Officer, effective February 27, 2025. Summary Compensation Table

| Name and Principal Position